LUND, Sweden, July 19, 2022 /PRNewswire/ --
"During the second quarter, sales in Sweden increased by 222% compared with the same period in 2021 and sales were also higher than the same period in 2020 and 2019. In those markets that are handled by our partners, our sales were on a par with the same period last year. The rights issue that was communicated today puts Enzymatica on solid ground for the years to come, including the possibility of more clinical studies as well as powerful marketing", said Claus Egstrand, CEO of Enzymatica.
The full year-end report is available on: www.enzymatica.com/investors/financial-reports
This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CETon 19 July 2022.
For more information, please contact:
Claus Egstrand, Chief Executive Officer, Enzymatica ABPhone: +44 7780 22 8385 | Email: email@example.com
Stefan Olsson, Communication Manager, Enzymatica ABPhone: +46 708 55 11 85 | Email: firstname.lastname@example.org
Enzymatica AB is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market. For more information, please visit www.enzymatica.se. Enzymatica's Certified Adviser is Erik Penser Bank. Tel: +46 8 463 83 00 Email: email@example.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download: